Review



recombinant il 32b  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    R&D Systems recombinant il 32b
    Recombinant Il 32b, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 12 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant il 32b/product/R&D Systems
    Average 93 stars, based on 12 article reviews
    recombinant il 32b - by Bioz Stars, 2026-05
    93/100 stars

    Images



    Similar Products

    recombinant il 32b  (R&D Systems)
    93
    R&D Systems recombinant il 32b
    Recombinant Il 32b, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant il 32b/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    recombinant il 32b - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    il-32b  (R&D Systems)
    90
    R&D Systems il-32b
    Il 32b, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/il-32b/product/R&D Systems
    Average 90 stars, based on 1 article reviews
    il-32b - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    human il 32b r d systems  (R&D Systems)
    93
    R&D Systems human il 32b r d systems
    Human Il 32b R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human il 32b r d systems/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    human il 32b r d systems - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    il 32b  (R&D Systems)
    94
    R&D Systems il 32b
    Figure 2. IL-32 induces CD14D APC that support malignant T-cell survival. (a) Survival of purified T cells versus PBMC from a patient with stage IV CTCL after culture with IL-32 and submitogenic IL-2. (b) <t>IL-32b</t> supported the survival of malignant and benign T cells and CD14þ myeloid cells. Five additional donors showed similar results. (c, d) HTS confirmed the persistence of malignant T cell TCRs in culture. (e) IL-32b enhanced the survival of benign and malignant T cells. (f, g) IL-32b induced the formation of large, activated CD14þ T cells. Similar results were observed in five additional donors. (h) The number of surviving malignant T cells was directly proportional to the number of IL-32beinduced large CD14þ cells. (i) IL-32b enhanced malignant T-cell survival by reducing apoptosis (detected by SYTOX Green). APC, antigen-presenting cell; cyt, cytokine; HTS, high throughput TCR sequencing.
    Il 32b, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/il 32b/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    il 32b - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier
    copyright 2021 wolters kluwer h il 32b  (Wolters Kluwer Health)
    86
    Wolters Kluwer Health copyright 2021 wolters kluwer h il 32b
    Figure 2. IL-32 induces CD14D APC that support malignant T-cell survival. (a) Survival of purified T cells versus PBMC from a patient with stage IV CTCL after culture with IL-32 and submitogenic IL-2. (b) <t>IL-32b</t> supported the survival of malignant and benign T cells and CD14þ myeloid cells. Five additional donors showed similar results. (c, d) HTS confirmed the persistence of malignant T cell TCRs in culture. (e) IL-32b enhanced the survival of benign and malignant T cells. (f, g) IL-32b induced the formation of large, activated CD14þ T cells. Similar results were observed in five additional donors. (h) The number of surviving malignant T cells was directly proportional to the number of IL-32beinduced large CD14þ cells. (i) IL-32b enhanced malignant T-cell survival by reducing apoptosis (detected by SYTOX Green). APC, antigen-presenting cell; cyt, cytokine; HTS, high throughput TCR sequencing.
    Copyright 2021 Wolters Kluwer H Il 32b, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/copyright 2021 wolters kluwer h il 32b/product/Wolters Kluwer Health
    Average 86 stars, based on 1 article reviews
    copyright 2021 wolters kluwer h il 32b - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier
    il-32b  (Federation of European Neuroscience Societies)
    90
    Federation of European Neuroscience Societies il-32b
    Figure 2. IL-32 induces CD14D APC that support malignant T-cell survival. (a) Survival of purified T cells versus PBMC from a patient with stage IV CTCL after culture with IL-32 and submitogenic IL-2. (b) <t>IL-32b</t> supported the survival of malignant and benign T cells and CD14þ myeloid cells. Five additional donors showed similar results. (c, d) HTS confirmed the persistence of malignant T cell TCRs in culture. (e) IL-32b enhanced the survival of benign and malignant T cells. (f, g) IL-32b induced the formation of large, activated CD14þ T cells. Similar results were observed in five additional donors. (h) The number of surviving malignant T cells was directly proportional to the number of IL-32beinduced large CD14þ cells. (i) IL-32b enhanced malignant T-cell survival by reducing apoptosis (detected by SYTOX Green). APC, antigen-presenting cell; cyt, cytokine; HTS, high throughput TCR sequencing.
    Il 32b, supplied by Federation of European Neuroscience Societies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/il-32b/product/Federation of European Neuroscience Societies
    Average 90 stars, based on 1 article reviews
    il-32b - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 2. IL-32 induces CD14D APC that support malignant T-cell survival. (a) Survival of purified T cells versus PBMC from a patient with stage IV CTCL after culture with IL-32 and submitogenic IL-2. (b) IL-32b supported the survival of malignant and benign T cells and CD14þ myeloid cells. Five additional donors showed similar results. (c, d) HTS confirmed the persistence of malignant T cell TCRs in culture. (e) IL-32b enhanced the survival of benign and malignant T cells. (f, g) IL-32b induced the formation of large, activated CD14þ T cells. Similar results were observed in five additional donors. (h) The number of surviving malignant T cells was directly proportional to the number of IL-32beinduced large CD14þ cells. (i) IL-32b enhanced malignant T-cell survival by reducing apoptosis (detected by SYTOX Green). APC, antigen-presenting cell; cyt, cytokine; HTS, high throughput TCR sequencing.

    Journal: The Journal of investigative dermatology

    Article Title: IL-32 Supports the Survival of Malignant T Cells in Cutaneous T-cell Lymphoma.

    doi: 10.1016/j.jid.2022.01.009

    Figure Lengend Snippet: Figure 2. IL-32 induces CD14D APC that support malignant T-cell survival. (a) Survival of purified T cells versus PBMC from a patient with stage IV CTCL after culture with IL-32 and submitogenic IL-2. (b) IL-32b supported the survival of malignant and benign T cells and CD14þ myeloid cells. Five additional donors showed similar results. (c, d) HTS confirmed the persistence of malignant T cell TCRs in culture. (e) IL-32b enhanced the survival of benign and malignant T cells. (f, g) IL-32b induced the formation of large, activated CD14þ T cells. Similar results were observed in five additional donors. (h) The number of surviving malignant T cells was directly proportional to the number of IL-32beinduced large CD14þ cells. (i) IL-32b enhanced malignant T-cell survival by reducing apoptosis (detected by SYTOX Green). APC, antigen-presenting cell; cyt, cytokine; HTS, high throughput TCR sequencing.

    Article Snippet: A total of 300,000e1,000,000 cells in 200 ml per well were cultured in round-bottom 96-well plates in the presence or absence of IL-2 (25 IU/ml, National Cancer Institute, Bethesda, MD), IL-32a (25 ng/ml; number 3040-IL-050, R&D Systems), IL-32b (25 ng/ml; number 6769-IL-025, R&D Systems), or IL-32g (25 ng/ml; number 4690-IL-025/CF, R&D Systems).

    Techniques: High Throughput Screening Assay, Sequencing